Purple Biotech Ltd. — Capital/Financing Update 2016

May 2, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL

Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

1. Issuer's Identity
CIK (Filer ID Number) 0001614744	Previous Names Mainrom Line	None	Entity Type Corporation
Name of Issuer Kitov Pharmaceuticals Holdings Ltd.	Logistics Ltd.		Limited Partnership Limited Liability Company
Jurisdiction of Incorporation/Organization ISRAEL			General Partnership
Year of Incorporation/Organization X Over Five Years Ago			Business Trust X Other (Specify)
Within Last Five Years (Specify Year)			Limited company
Yet to Be Formed
2. Principal Place of Business and Contact Information
Name of Issuer
Kitov Pharmaceuticals Holdings Ltd.
Street Address 1			Street Address 2
ONE AZRIELI CENTER,		ROUND BUILDING, 23RD FLOOR
City TEL AVIV	State/Province/Country ISRAEL	ZIP/PostalCode 6701101	Phone Number of Issuer 011972525328200
3. Related Persons
Last Name	First Name		Middle Name
Israel Street Address 1	Isaac Street Address 2
One Azrieli Center,	Round Building, 23rd Floor
City Tel Aviv	State/Province/Country ISRAEL		ZIP/PostalCode 6701101
Relationship: X	Executive Officer X	Director Promoter
Clarification of Response (if Necessary):
Last Name Rock	First Name Simcha		Middle Name
Street Address 1	Street Address 2
One Azrieli Center, City	Round Building, 23rd Floor State/Province/Country		ZIP/PostalCode
Tel Aviv	ISRAEL		6701101
Relationship: X	Executive Officer X	Director Promoter
Clarification of Response (if Necessary):

OMB Number: 3235-0076

4.00

Estimated average burden hours per response

One Azrieli Center, City Tel Aviv Relationship: X Executive Officer	Round Building, 23rd Floor State/Province/Country ISRAEL X Director Promoter	ZIP/PostalCode 6701101
Clarification of Response (if Necessary):
Last Name Katzir Street Address 1 One Azrieli Center, City Tel Aviv Relationship: Executive Officer Clarification of Response (if Necessary):	First Name Yair Street Address 2 Round Building, 23rd Floor State/Province/Country ISRAEL X Director Promoter	Middle Name ZIP/PostalCode 6701101
Last Name Sherf-Blau Street Address 1 One Azrieli Center, City Tel Aviv Relationship: Executive Officer	First Name Moran Street Address 2 Round Building, 23rd Floor State/Province/Country ISRAEL X Director Promoter	Middle Name ZIP/PostalCode 6701101
Clarification of Response (if Necessary):
Last Name Zeitoun Street Address 1 One Azrieli Center, City Tel Aviv Relationship: Executive Officer	First Name Alain Street Address 2 Round Building, 23rd Floor State/Province/Country ISRAEL X Director Promoter	Middle Name ZIP/PostalCode 6701101
Clarification of Response (if Necessary):
Last Name Ben-Menachem Street Address 1 One Azrieli Center,	First Name Gil Street Address 2 Round Building, 23rd Floor	Middle Name
City Tel Aviv Relationship:	State/Province/Country ISRAEL Director	ZIP/PostalCode 6701101
X Executive Officer Promoter Clarification of Response (if Necessary):
4. Industry Group
Agriculture Banking & Financial Services	Health Care Biotechnology	Retailing Restaurants

Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities	Health Insurance Hospitals & Physicians X Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial Construction REITS & Finance Residential Other Real Estate	Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel Other
Energy Conservation Environmental Services Oil & Gas Other Energy

5. Issuer Size

Revenue Range No Revenues	OR	Aggregate Net Asset Value Range No Aggregate Net Asset Value
\$1 - \$1,000,000 \$1,000,001 - \$5,000,000 \$5,000,001 - \$25,000,000		\$1 - \$5,000,000 \$5,000,001 - \$25,000,000 \$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000 X Decline to Disclose		Over \$100,000,000 Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Section 3(c)(7)
7. Type of Filing
X New Notice Date of First Sale 2016-05-02 Amendment	First Sale Yet to Occur
8. Duration of Offering
Does the Issuer intend this offering to last more than one year? Yes X No
9. Type(s) of Securities Offered (select all that apply)
X Equity Debt Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other (describe)
10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Clarification of Response (if Necessary):	Yes No X
11. Minimum Investment
Minimum investment accepted from any outside investor \$ 0 USD
12. Sales Compensation
Recipient Recipient CRD Number	X None
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
Street Address 1 Street Address 2
City State/Province/Country ZIP/Postal Code
State(s) of Solicitation All States Non-US/Foreign AL AK AZ AR CA CO CT DE IL IN IA KS KY LA ME MD MT NE NV NH NJ NM NY NC RI SC SD TN TX UT VT VA 13. Offering and Sales Amounts	DC FL GA HI ID MA MI MN MS MO ND OH OK OR PA WA WV WI WY PR

Total Offering Amount	\$	USD	or X Indefinite
Total Amount Sold	\$ 0	USD
Total Remaining to be Sold	\$	USD	or X Indefinite

Clarification of Response (if Necessary):

A private placement to a vendor of the Filer of 9,455 of the Filer's ADSs which have been issued, and which are being offered in consideration for services provided by the vendor to the Filer.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 1

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	0 \$ USD	Estimate
Finders' Fees	\$ 0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

0 \$	USD		Estimate
---------	-----	--	----------

Clarification of Response (if Necessary):

See clarification to item 13 above.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and submitting this notice.

Terms of Submission

In submitting this notice, each identified issuer is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
• Irrevocably appointing each of the Secretary of the SEC and the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in

which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes; or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Kitov Pharmaceuticals Holdings Ltd.	/s/Simcha Rock	Simcha Rock	Chief Financial Officer and Director	2016-05-02

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.